Welcome to our dedicated page for Carisma Therapeutics SEC filings (Ticker: CARM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Carisma Therapeutics’ biotech disclosures can feel like reading advanced immunology. The company’s CAR-M pipeline, Moderna collaboration, and multi-indication studies load each 10-K and 10-Q with dense data on R&D burn, cGMP manufacturing, and trial risk factors. Even a one-page 8-K may hide a pivotal HER2 update investors cannot ignore.
Stock Titan eliminates that blind spot. Our AI delivers Carisma Therapeutics SEC filings explained simply: every Carisma Therapeutics annual report 10-K simplified, every Carisma Therapeutics quarterly earnings report 10-Q filing annotated, and each Carisma Therapeutics earnings report filing analysis ready the moment EDGAR posts. Need alerts? Carisma Therapeutics Form 4 insider transactions real-time are flagged seconds after submission, so you track Carisma Therapeutics insider trading Form 4 transactions without scanning pages of legalese.
Use our tools to answer real questions faster:
- Monitor Carisma Therapeutics executive stock transactions Form 4 to gauge management confidence.
- Compare pipeline spending across quarters with AI-tagged cash-runway metrics.
- Dive into the proxy statement executive compensation tables without wrestling with footnotes.
- See every Carisma Therapeutics 8-K material events explained in plain English within minutes of filing.
Carisma Therapeutics (CARM) filed its Q3 report, highlighting a wind down strategy and going‑concern risk. The company reported $45.3 million in collaboration revenue in Q3, driven by recognition of deferred amounts and a $4.0 million one‑time payment from a September 16, 2025 amendment to its Moderna agreement. This produced net income of $44.7 million (EPS $1.07) for the quarter.
Cash and cash equivalents were $2.8 million as of September 30, 2025, and management stated substantial doubt about continuing as a going concern. Deferred revenue fell to zero from $45.0 million, total liabilities were $7.4 million, and stockholders’ deficit narrowed to $0.9 million.
The planned merger with OrthoCellix was terminated on September 16, 2025; Carisma recorded a $1.3 million receivable for a termination fee and expense reimbursement. Trading of its common stock on Nasdaq was suspended October 13, 2025, and shares now trade on the OTCID market. Carisma has ceased R&D, is pursuing asset monetizations, and is preparing an orderly wind down; it may file a Form 15 to suspend SEC reporting and notes it is unlikely a meaningful cash amount will be available for stockholder distribution.
Carisma Therapeutics (CARM) announced leadership changes aligned with an orderly wind down and asset monetization plan. The Company will terminate CEO Steven Kelly without cause effective November 15, 2025, and CSO Michael Klichinsky, Pharm.D., Ph.D., effective October 15, 2025. Each entered into separation agreements providing 12 months of base salary, a lump sum equal to 100% of 2025 target bonus pro‑rated to their departure dates, and taxable monthly payments for up to 12 months to offset health insurance costs: $3,757 for Mr. Kelly and $2,245 for Dr. Klichinsky.
The Company expects to appoint a consultant to serve as chief executive officer to manage remaining wind‑down activities. Directors John Hohneker, M.D., Briggs Morrison, M.D., and David Scadden, M.D., resigned effective October 15, 2025, and Mr. Kelly will resign from the Board effective November 15, 2025; the resignations were not due to disagreements with Company policies or practices.
Michael Klichinsky, Chief Scientific Officer of Carisma Therapeutics, Inc. (CARM), exercised stock options and sold the resulting shares on
Carisma Therapeutics, Inc. (CARM) filed a Form 144 notifying a proposed sale under Rule 144 of 56,982 common shares held by an insider who acquired the shares via an option grant on
Carisma Therapeutics, Inc. (CARM) submitted a Form 144 notifying of a proposed sale of 484,347 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value listed as $134,164.12. The filing reports 41,788,096 shares outstanding and names 09/30/2025 as the approximate sale date on NASDAQ. The shares were acquired as founder stock on 05/31/2017 from the issuer, and the filing indicates the payment/nature of disposition as compensation. The filer reports no sales in the past three months. Several identifying filer and contact fields are not provided in the notice.
Amendment No. 6 to a Schedule 13D for Carisma Therapeutics, Inc. (CARM) corrects prior reporting and discloses that HealthCap VII, L.P. and related reporting persons sold multiple blocks of common stock in August and early September 2025. The filing lists specific transactions: 147,884 shares on August 22 at $0.231, 92,900 shares on August 25 at $0.231, 80,201 shares on August 26 at $0.235, 110,214 shares on August 27 at $0.229, 82,194 shares on August 28 at $0.22765, 91,852 shares on August 29 at $0.22037, and 2,116,678 shares on September 2 at $0.46802. The reporting persons state they ceased to be beneficial owners of more than 5% of the common stock as of September 2, 2025. The amendment also corrects previously reported share counts and sale quantities from Amendment No. 5.
HealthCap VII, L.P. and its related entities report beneficial ownership of 2,014,372 shares of Carisma Therapeutics Inc. common stock, equal to 4.8% of the class based on 41,788,096 shares outstanding as of August 5, 2025. The filing amends prior Schedule 13D disclosures to report open-market sales totaling 707,551 shares executed August 22–29, 2025 at prices ranging from $0.22037 to $0.24667 per share. Following the sales, the reporting persons stated they ceased to be beneficial owners of more than 5% of the common stock as of August 29, 2025. The cover pages identify the reporting entities as Delaware-organized and list source-of-funds codes provided on the cover pages.
FAQ
What is the current stock price of Carisma Therapeutics (CARM)?
What is the market cap of Carisma Therapeutics (CARM)?
